BioCentury | Oct 28, 2020
Product Development

Data Byte: FOLR1 pipeline for cancer

...FOLR1 are in development to treat cancer. The lead program is in Phase III testing for ovarian cancer.ImmunoGen Inc....
...– Folate receptor 1 Danielle Golovin farletuzumab (MORAb-003) MOv18 IgE mirvetuximab soravtansine (IMGN853) MORAb-202 STRO-002 TPIV200 (TPIV 200, TPIV200/huFR-1) Folate receptor alpha peptide vaccine ImmunoGen Inc. Eisai...
BioCentury | Oct 24, 2020
Product Development

Oct. 23 Quick Takes: Ultragenyx, Solid in DMD gene therapy deal; plus IAVI-Merck KGaA-Serum Institute, BiondVax, Retrophin-Orphan Technologies, and more

Ultragenyx, Solid Bio in deal for DMD gene therapyUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) is collaborating with Solid Biosciences Inc. (NASDAQ:SLDB) to develop a gene therapy for Duchenne muscular...
BioCentury | Oct 23, 2020
Emerging Company Profile

Be Bio: bringing the B to cell therapy

Be Biopharma launched Thursday with a $52 million series A round led by Atlas Venture and RA Capital and a platform to engineer B cells that could overcome the durability, safety and re-dosing challenges of existing cell...
BioCentury | Oct 20, 2020
Product Development

Data Byte: COVID-19 vaccine readouts suggest wide range of age-dependent effects on antibody responses

The first clinical readouts for five COVID-19 vaccines suggest a wide range of age-dependent effects on antibody responses. Whether those differences hold up in larger populations or turn out to be clinically meaningful will be...
BioCentury | Oct 19, 2020
Deals

ImmunoGen chooses Huadong’s $40M upfront offer for Greater China rights to ADC

...By Paul Bonanos, Associate Editor ImmunoGen has been signaling for months that it would soon strike...
...Co. Ltd. (SZSE:000963) obtained a license covering mainland China, Hong Kong, Macau and Taiwan for ImmunoGen’s...
...in 2022.On the company’s 1Q20 earnings call in May, President and CEO Mark Enyedy said ImmunoGen...
BioCentury | Oct 16, 2020
Product Development

WHO data show quartet of therapies fail to reduce COVID death

Data from WHO’s SOLIDARITY trial reiterate the results of NIH’s ACTT: Veklury does not provide a survival benefit in COVID-19. The interim results from WHO’s open-label master protocol trial, published Thursday in medRxiv, showed that Veklury remdesivir...
BioCentury | Oct 14, 2020
Product Development

A third leading COVID program enters holding pattern as NIH pauses testing of Lilly’s mAb

The launch of NIH’s Phase II ACTIV-5 Big Effect Trial study of anti-inflammatory mAbs Skyrizi from AbbVie and Boehringer and lenzilumab from Humanigen to treat hospitalized COVID-19 patients has coincided...
BioCentury | Oct 12, 2020
Product Development

Data Bytes: COVID-19 vaccines by phase and modality

Among the 201 COVID-19 vaccines in development, at least 43 have reached the clinic. Each vaccine modality comes with a different set of pros and cons and varying levels and durations of immunity. Russia approved Sputnik V,...
BioCentury | Oct 2, 2020
Regulation

Oct. 1 Quick Takes: Setback at FDA for Mesoblast; plus AMAG, Solid, COVID updates from Gilead, AZ and more

Bucking ODAC recommendation, FDA wants another trial from MesoblastMesoblast Ltd. (ASX:MSB; NASDAQ:MESO) said FDA issued a complete response letter to a BLA for remestemcel-L to treat pediatric steroid-refractory acute GvHD. FDA’s Oncologic Drugs Advisory Committee had voted 9...
BioCentury | Sep 25, 2020
Product Development

Antibody, T cell responses for J&J COVID-19 vaccine support Phase III dose and regimen

Interim Phase I/II data for J&J’s COVID-19 vaccine show its ability to induce neutralizing antibodies via a single immunization is maintained in the elderly, like Moderna’s candidate, and demonstrates...
Items per page:
1 - 10 of 3140
BioCentury | Oct 28, 2020
Product Development

Data Byte: FOLR1 pipeline for cancer

...FOLR1 are in development to treat cancer. The lead program is in Phase III testing for ovarian cancer.ImmunoGen Inc....
...– Folate receptor 1 Danielle Golovin farletuzumab (MORAb-003) MOv18 IgE mirvetuximab soravtansine (IMGN853) MORAb-202 STRO-002 TPIV200 (TPIV 200, TPIV200/huFR-1) Folate receptor alpha peptide vaccine ImmunoGen Inc. Eisai...
BioCentury | Oct 24, 2020
Product Development

Oct. 23 Quick Takes: Ultragenyx, Solid in DMD gene therapy deal; plus IAVI-Merck KGaA-Serum Institute, BiondVax, Retrophin-Orphan Technologies, and more

Ultragenyx, Solid Bio in deal for DMD gene therapyUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) is collaborating with Solid Biosciences Inc. (NASDAQ:SLDB) to develop a gene therapy for Duchenne muscular...
BioCentury | Oct 23, 2020
Emerging Company Profile

Be Bio: bringing the B to cell therapy

Be Biopharma launched Thursday with a $52 million series A round led by Atlas Venture and RA Capital and a platform to engineer B cells that could overcome the durability, safety and re-dosing challenges of existing cell...
BioCentury | Oct 20, 2020
Product Development

Data Byte: COVID-19 vaccine readouts suggest wide range of age-dependent effects on antibody responses

The first clinical readouts for five COVID-19 vaccines suggest a wide range of age-dependent effects on antibody responses. Whether those differences hold up in larger populations or turn out to be clinically meaningful will be...
BioCentury | Oct 19, 2020
Deals

ImmunoGen chooses Huadong’s $40M upfront offer for Greater China rights to ADC

...By Paul Bonanos, Associate Editor ImmunoGen has been signaling for months that it would soon strike...
...Co. Ltd. (SZSE:000963) obtained a license covering mainland China, Hong Kong, Macau and Taiwan for ImmunoGen’s...
...in 2022.On the company’s 1Q20 earnings call in May, President and CEO Mark Enyedy said ImmunoGen...
BioCentury | Oct 16, 2020
Product Development

WHO data show quartet of therapies fail to reduce COVID death

Data from WHO’s SOLIDARITY trial reiterate the results of NIH’s ACTT: Veklury does not provide a survival benefit in COVID-19. The interim results from WHO’s open-label master protocol trial, published Thursday in medRxiv, showed that Veklury remdesivir...
BioCentury | Oct 14, 2020
Product Development

A third leading COVID program enters holding pattern as NIH pauses testing of Lilly’s mAb

The launch of NIH’s Phase II ACTIV-5 Big Effect Trial study of anti-inflammatory mAbs Skyrizi from AbbVie and Boehringer and lenzilumab from Humanigen to treat hospitalized COVID-19 patients has coincided...
BioCentury | Oct 12, 2020
Product Development

Data Bytes: COVID-19 vaccines by phase and modality

Among the 201 COVID-19 vaccines in development, at least 43 have reached the clinic. Each vaccine modality comes with a different set of pros and cons and varying levels and durations of immunity. Russia approved Sputnik V,...
BioCentury | Oct 2, 2020
Regulation

Oct. 1 Quick Takes: Setback at FDA for Mesoblast; plus AMAG, Solid, COVID updates from Gilead, AZ and more

Bucking ODAC recommendation, FDA wants another trial from MesoblastMesoblast Ltd. (ASX:MSB; NASDAQ:MESO) said FDA issued a complete response letter to a BLA for remestemcel-L to treat pediatric steroid-refractory acute GvHD. FDA’s Oncologic Drugs Advisory Committee had voted 9...
BioCentury | Sep 25, 2020
Product Development

Antibody, T cell responses for J&J COVID-19 vaccine support Phase III dose and regimen

Interim Phase I/II data for J&J’s COVID-19 vaccine show its ability to induce neutralizing antibodies via a single immunization is maintained in the elderly, like Moderna’s candidate, and demonstrates...
Items per page:
1 - 10 of 3140